{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:10Z","timestamp":1781179090017,"version":"3.54.1"},"reference-count":24,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Background\u2003Epithelial ovarian cancer (EOC) is one of the leading causes of cancer-related death in women. Approximately 70% of patients with EOC are diagnosed in advanced stage [The International Federation of Gynecology and Obstetrics(FIGO stage III and IV)] with an expected 5-year survival rate of 30%. Numerous studies have shown that survival with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is noninferior to primary debulking surgery followed by chemotherapy.<\/jats:p>\n                  <jats:p>Materials and Methods\u2003In this retroprospective observational study, 50 patients with advanced ovarian cancer, diagnosed from January 2012 to January 2015, were included and followed-up till January 2017. Correlation of NACT with patient profile, CA125 levels, clinicopathologic parameters, progression-free survival (PFS), and treatment response was studied. Statistical analysis was performed using log-rank test and Kaplan-Meir survival plots.<\/jats:p>\n                  <jats:p>Results\u2003The extent of cytoreduction significantly correlated with PFS. The PFS was maximum in patients who had optimal cytoreduction (19 months) and 10 months in patients with suboptimal cytoreduction with p-value\u2009&lt;\u20090.05. The survival was not significantly correlated with other parameters such as age, stage, preoperative CA125 levels, and ascites.<\/jats:p>\n                  <jats:p>Conclusions\u2003The extent of cytoreduction following NACT in this study was associated with statistically significant PFS advantage in patients who were able to undergo optimal cytoreduction, but not significantly correlated to other factors such as age, stage, preoperative CA125 levels, and ascites. NACT followed by interval cytoreduction is an important modality affecting survival in advanced EOC. Further studies and longer follow-up are needed to demonstrate survival advantage over standard treatment.<\/jats:p>","DOI":"10.1055\/s-0042-1754441","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T19:12:21Z","timestamp":1657566741000},"page":"207-212","source":"Crossref","is-referenced-by-count":1,"title":["Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?"],"prefix":"10.25259","volume":"11","author":[{"given":"Pravesh","family":"Dhiman","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of RT and Oncology, IGMC, Shimla, Himachal Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.P.","family":"Bapsy","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medical Oncology, Apollo Hospitals, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Patil","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medical Oncology, Apollo Hospitals, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Raghupathi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medical Oncology, Apollo Hospitals, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"R Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"ref2","first-page":"1075","volume-title":"Ovarian cancer, Fallopian tube carcinoma and peritoneal cancer","author":"A Stephen","year":"2015"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"S Vaughan","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"R Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"L A Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynaecological cancer: the size of the problem","volume":"20","author":"R Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3332\/ecancer.2016.628","article-title":"The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia","volume":"10","author":"S Razi","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"17","key":"ref11","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"R F Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref12","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"A du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"S 10","key":"ref13","doi-asserted-by":"crossref","first-page":"x118","DOI":"10.1093\/annonc\/mds315","article-title":"Optimal first-line treatment in ovarian cancer","volume":"23","author":"F A Raja","year":"2012","journal-title":"Ann Oncol"},{"issue":"26","key":"ref14","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"R A Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"ref15","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"T J Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"B Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a Phase II, randomised, double-blind, placebo-controlled trial","volume":"17","author":"J A Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"E M Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref19","first-page":"15","article-title":"Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): a prospective, randomized study","volume":"30","author":"L Kumar","year":"2009","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref20","first-page":"953509","article-title":"Recent advancements in prognostic factors of epithelial ovarian carcinoma","volume":"2014","author":"M Ezzati","year":"2014","journal-title":"Int Sch Res Notices"},{"issue":"24","key":"ref21","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"W E Winter III","year":"2007","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/cncr.20920","article-title":"The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma","volume":"103","author":"R Eitan","year":"2005","journal-title":"Cancer"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13048-016-0294-z","article-title":"Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer","volume":"9","author":"X Xu","year":"2016","journal-title":"J Ovarian Res"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1525-1438.2005.00145.x","article-title":"Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma","volume":"15","author":"B Gronlund","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-2-13","article-title":"Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature","volume":"2","author":"D Gupta","year":"2009","journal-title":"J Ovarian Res"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0971-5851.151781","article-title":"Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a survival study","volume":"36","author":"U Baruah","year":"2015","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"464123","DOI":"10.1155\/2015\/464123","article-title":"Prognostic value of residual disease after interval debulking surgery for FIGO stage IIIC and IV epithelial ovarian cancer","volume":"2015","author":"M J Rutten","year":"2015","journal-title":"Obstet Gynecol Int"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1754441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:34Z","timestamp":1781176354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/is-optimal-cytoreduction-post-neoadjuvant-chemotherapy-the-only-prognostic-factor-in-advanced-ovarian-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":24,"aliases":["10.1055\/s-0042-1755291","10.1055\/s-0042-1755291"],"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,12,30]]},"published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1754441","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}